Blood advances
Circulating MRP8/14 drives faster platelet COX-1 recovery via MRP4 impairing the duration of aspirin response.
Rossella Liani, Paola Giustina Simeone, Margherita Alfonsetti, Stefano Lattanzio, Alessia Ricci, Maurizio Frezza, Sonia Ciotti, Myriam Luongo, Francesco Cipollone, Fabio M Pulcinelli, Francesca Santilli
Published: 202510.1182/bloodadvances.2025017653
Abstract
Low-dose aspirin is a cornerstone of cardiovascular prevention in high-risk patients, inhibiting platelet cyclooxygenase (COX-1) and reducing thromboxane (TX) A2 production for 24 hours. However, the duration of this effect varies among individuals,…
Preview only. Read the full abstract at the source